Premium
Determination of 4‐bromo‐2,5‐dimethoxy‐N‐[(2‐methoxyphenyl)methyl]‐benzeneethanamine (25B‐NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication
Author(s) -
Poklis Justin L.,
Nanco Carol R.,
Troendle Michelle M.,
Wolf Carl E.,
Poklis Alphonse
Publication year - 2013
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.1522
Subject(s) - chemistry , chromatography , urine , designer drug , high performance liquid chromatography , mass spectrometry , phenethylamines , tandem mass spectrometry , derivative (finance) , pharmacology , drug , medicine , stereochemistry , biochemistry , financial economics , economics
We present a case of 4‐bromo‐2,5‐dimethoxy‐N‐[(2‐methoxyphenyl)methyl]‐benzeneethanamine (25B‐NBOMe), an N‐benzyl phenethylamines derivative, intoxication and a high performance liquid chromatography with tandem mass spectrometry (HPLC‐MS/MS) method for detection and quantification of 25B‐NBOMe. A 19‐year‐old male was found unresponsive with generalized grand mal seizure activity. On the second day of hospitalization, a friend admitted that the patient used ‘some unknown drug’ called 25B. Serum and urine collected were sent to the Virginia Commonwealth University Medical Center Toxicology Laboratory for analysis. An HPLC‐MS/MS method for the identification and quantification of 25B‐NBOMe using 2‐(2,5‐dimethoxyphenyl)‐N‐(2‐methoxybenzyl)ethanamine (25H‐NBOMe) as the internal standard (ISTD) was developed. As this is a novel, single‐case presentation, an assay validation was performed prior to testing to ensure the reliability of the analytical results. The serum and urine specimens were determined to contain 180 pg/ml and1900 pg/ml of 25B‐NBOMe, respectively. Copyright © 2013 John Wiley & Sons, Ltd.